Gilead Sciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GILD Nasdaq 2836 www.gilead.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gilead Sciences, Inc.

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Jun 8th, 2026 2:35 pm
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study - Jun 8th, 2026 2:30 pm
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead - Jun 8th, 2026 11:03 am
Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says - Jun 8th, 2026 9:00 am
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now? - Jun 7th, 2026 2:11 pm
Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline - Jun 6th, 2026 10:39 pm
SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens. - Jun 6th, 2026 8:10 am
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands - Jun 5th, 2026 1:03 pm
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa - Jun 5th, 2026 1:00 am
Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Jun 4th, 2026 6:08 pm
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline - Jun 4th, 2026 2:15 pm
GILD Reports Positive Results From Late-Stage Liver Disease Study - Jun 3rd, 2026 9:18 am
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness - Jun 3rd, 2026 7:12 am
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Jun 3rd, 2026 7:00 am
Gilead eyes PBC expansion for Livdelzi on positive one-year data - Jun 3rd, 2026 5:09 am
How Investors Are Reacting To Gilead Sciences (GILD) Expanding Liver And Oncology Drug Footprint - Jun 2nd, 2026 6:16 pm
Gilead Sciences (GILD) Announces New Results From a Post Hoc Analysis - Jun 2nd, 2026 8:14 am
Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety - Jun 2nd, 2026 8:11 am
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) - Jun 2nd, 2026 6:30 am
Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies - Jun 2nd, 2026 6:00 am